Cytokine release syndrome, grade 1
ICD-10 D89.831 is a billable code used to indicate a diagnosis of cytokine release syndrome, grade 1.
Cytokine release syndrome (CRS) is a systemic inflammatory response that can occur following certain therapies, particularly immunotherapies such as CAR T-cell therapy or monoclonal antibodies. Grade 1 CRS is characterized by mild symptoms, which may include fever, fatigue, and mild hypotension, but does not require intensive medical intervention. The pathophysiology involves the activation of immune cells leading to the release of pro-inflammatory cytokines, which can cause a cascade of inflammatory responses. In grade 1 CRS, the symptoms are generally self-limiting and resolve with supportive care. Monitoring is essential to ensure that symptoms do not escalate to higher grades of CRS, which can lead to more severe complications such as organ dysfunction. Accurate coding of CRS is crucial for appropriate treatment documentation and reimbursement, as well as for tracking the incidence of this condition in patients undergoing specific therapies.
Detailed documentation of treatment history, symptom onset, and grading of CRS.
Patients receiving CAR T-cell therapy experiencing mild fever and fatigue.
Ensure that the immunotherapy type is clearly documented to support the diagnosis of CRS.
Comprehensive records of immune response assessments and cytokine levels.
Patients with autoimmune disorders receiving monoclonal antibodies showing mild CRS symptoms.
Document any pre-existing conditions that may influence CRS severity.
Used when administering immunotherapy that may lead to CRS.
Document the type of chemotherapy and any observed side effects.
Oncology specialists should ensure that CRS symptoms are documented during treatment.
Grade 1 CRS symptoms typically include mild fever, fatigue, and mild hypotension. These symptoms are generally self-limiting and do not require intensive medical intervention.
Diagnosis is based on clinical symptoms, treatment history, and the grading of symptoms according to established criteria. Documentation of the patient's immunotherapy treatment is essential.
